J. Thomas

发表

Overcoming steric effects in the coupling reaction of alkyloxycarbonyloxymethyl (AOCOM) halides with phenols: an efficient synthesis of AOCOM phenolic prodrugs

K. Sloan, J. Thomas, 2007 .

Soft Alkyl Ether Prodrugs of a Model Phenolic Drug: The Effect of Incorporation of Ethyleneoxy Groups on Transdermal Delivery

S. Majumdar, K. Sloan, J. Thomas, 2009, Molecules.

Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.

T. Burke, T. Hofer, C. Rader, 2008, Bioorganic & medicinal chemistry letters.

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy.

N. Bodyak, D. Gumerov, Liuliang Qin, 2015, Cancer research.

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

D. Bergstrom, M. Protopopova, N. Bodyak, 2021, Molecular Cancer Therapeutics.

Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates.

T. Burke, T. Hofer, C. Rader, 2012, Bioconjugate chemistry.

Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.

A. Wiestner, T. Burke, C. Rader, 2014, Cancer research.

Harnessing the Fc m Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia

A. Wiestner, T. Burke, C. Rader, 2014 .

In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen.

K. Sloan, J. Thomas, 2008, International journal of pharmaceutics.

Chemically Programmed Bispecific Antibodies That Recruit and Activate T Cells*

T. Burke, C. Rader, Huiting Cui, 2012, The Journal of Biological Chemistry.

Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors

D. Bergstrom, N. Bodyak, L. Poling, 2015 .

Discovery of Novel Polyamide-Pyrrolobenzodiazepine Hybrids for Antibody-Drug Conjugates.

N. Bodyak, D. Gumerov, Liuliang Qin, 2022, Bioorganic & medicinal chemistry letters.

IMPROVING THE TOPICAL DELIVERY OF PHENOL-CONTAINING DRUGS: AN ALKYLCARBONYLOXYMETHYL AND ALKYLOXYCARBONYLOXYMETHYL PRODRUG APPROACH

J. Thomas, Joshua D Thomas, 2006 .

α-(1H-Imidazol-1-yl)alkyl (IMIDA) carboxylic acid esters as prodrugs of carboxylic acid containing drugs

J. Juntunen, S. Majumdar, K. Sloan, 2007 .

Evaluation of alkyloxycarbonyloxymethyl (AOCOM) ethers as novel prodrugs of phenols for topical delivery: AOCOM prodrugs of acetaminophen.

J. Thomas, Kenneth B Sloan, 2009, International journal of pharmaceutics.

Reaction of alkylcarbonyloxymethyl halides with phenols: reevaluating the influence of steric hindrance

K. Sloan, J. Thomas, 2006 .

Improvement in dye sensitized solar cell efficiency through functionalization of redox mediators and passivation of the photoanode using a home-built atomic layer deposition system

J. Thomas, 2018 .

Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells

Jeremy R. Duvall, M. Protopopova, M. Damelin, 2022, Cancer Research.

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, M. Protopopova, S. Collins, 2022, Cancer Research.

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, M. Protopopova, S. Collins, 2021, Immunology.

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Jeremy R. Duvall, M. Protopopova, S. Collins, 2020 .

Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets

N. Bodyak, L. Poling, M. Devit, 2014 .

An engineered selenocysteine defines a unique class of antibody derivatives

T. Burke, T. Hofer, C. Rader, 2008, Proceedings of the National Academy of Sciences.